Interesting that this stock is just 7 % above pre-covid level, looking at the performance since FY 19.
FY 19-FY 23 performance :
. + 71 % for number of stores,
. + 15 % lfl sales,
. + 211 % for digital sales (it went from 10 % of total sales to 19 % now),
. + 80 % for revenues,
. + 61 % for EPS,
. + 112 % for dividend.
The picture is not very different if we look at the most recent period when there was a sudden deterioration of consumption :
- H2 23 EBITDA : + 11 % yoy with + 12 % yoy for sales (+ 8 % lfl),
- first 7 weeks of FY 24 : + 2.8 % for sales, with stable gross margin.
- Forums
- ASX - By Stock
- Ann: FY23 Full-Year Investor Presentation
Interesting that this stock is just 7 % above pre-covid level,...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AX1 (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.32 |
Change
-0.030(1.28%) |
Mkt cap ! $1.313B |
Open | High | Low | Value | Volume |
$2.35 | $2.36 | $2.31 | $1.384M | 594.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 16279 | $2.31 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.33 | 2410 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 16279 | 2.310 |
2 | 27500 | 2.300 |
2 | 6585 | 2.290 |
1 | 2081 | 2.280 |
1 | 1908 | 2.270 |
Price($) | Vol. | No. |
---|---|---|
2.330 | 2410 | 1 |
2.340 | 7251 | 1 |
2.350 | 25911 | 6 |
2.360 | 11533 | 3 |
2.370 | 23299 | 5 |
Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
Featured News
AX1 (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham, MD & CEO
James Graham
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online